Show simple item record

dc.contributor.authorOst, P
dc.contributor.authorJereczek-Fossa, BA
dc.contributor.authorVan As, N
dc.contributor.authorZilli, T
dc.contributor.authorTree, A
dc.contributor.authorHenderson, D
dc.contributor.authorOrecchia, R
dc.contributor.authorCasamassima, F
dc.contributor.authorSurgo, A
dc.contributor.authorMiralbell, R
dc.contributor.authorDe Meerleer, G
dc.date.accessioned2021-02-24T10:59:18Z
dc.date.available2021-02-24T10:59:18Z
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2016, 28 (9), pp. e115 - e120en_US
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4362
dc.identifier.eissn1433-2981en_US
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2016.04.040en_US
dc.identifier.doi10.1016/j.clon.2016.04.040
dc.description.abstract<h4>Aims</h4>To report the relapse pattern of stereotactic body radiotherapy (SBRT) for oligorecurrent nodal prostate cancer (PCa).<h4>Materials and methods</h4>PCa patients with ≤3 lymph nodes (N1/M1a) at the time of recurrence were treated with SBRT. SBRT was defined as a radiotherapy dose of at least 5 Gy per fraction to a biological effective dose of at least 80 Gy to all metastatic sites. Distant progression-free survival was defined as the time interval between the first day of SBRT and appearance of new metastatic lesions, outside the high-dose region. Relapses after SBRT were recorded and compared with the initially treated site. Secondary end points were local control, time to palliative androgen deprivation therapy and toxicity scored using the Common Terminology Criteria for Adverse Events v4.0.<h4>Results</h4>Overall, 89 metastases were treated in 72 patients. The median distant progression-free survival was 21 months (95% confidence interval 16-25 months) with 88% of patients having ≤3 metastases at the time of progression. The median time from first SBRT to the start of palliative androgen deprivation therapy was 44 months (95% confidence interval 17-70 months). Most relapses (68%) occurred in nodal regions. Relapses after pelvic nodal SBRT (n = 36) were located in the pelvis (n = 14), retroperitoneum (n = 1), pelvis and retroperitoneum (n = 8) or in non-nodal regions (n = 13). Relapses after SBRT for extrapelvic nodes (n = 5) were located in the pelvis (n = 1) or the pelvis and retroperitoneum (n = 4). Late grade 1 and 2 toxicity was observed in 17% (n = 12) and 4% of patients (n = 3).<h4>Conclusion</h4>SBRT for oligometastatic PCa nodal recurrences is safe. Most subsequent relapses are again nodal and oligometastatic.en_US
dc.formatPrint-Electronicen_US
dc.format.extente115 - e120en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectLymph Nodesen_US
dc.subjectHumansen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectLymphatic Metastasisen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectDisease Progressionen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectRadiosurgeryen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectMaleen_US
dc.titlePattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-03-15
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1016/j.clon.2016.04.040en_US
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))en_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume28en_US
pubs.embargo.termsNot knownen_US
icr.researchteamStereotactic and Precision Body Radiotherapy
dc.contributor.icrauthorvan As, Nicken_US
dc.contributor.icrauthorTree, Alisonen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record